This transcript has been edited for clarity. Hello, my name is Van Morris. I’m a medical oncology physician at MD Anderson Cancer Center who takes care of patients with lower GI cancers. I’m excited to talk today about updates in anal cancer. Anal cancer is a rare cancer linked to prior infection with the human … Read more
TOPLINE: Moderately hypofractionated radiotherapy, both isodose and dose-escalated, led to progression-free survival outcomes similar to that achieved with conventionally fractionated radiotherapy in patients with prostate cancer, but the dose-escalated regimen came with an increased risk for toxicities compared with the conventional approach, according to findings from a recent meta-analysis. METHODOLOGY: Moderately hypofractionated radiotherapy is now … Read more
New findings on radiation plus adjuvant chemotherapy in patients with intermediate-risk cervical cancer seem to spell the end for the dual therapy in this group. Results from a phase 3 clinical trial of 316 women who’d had radical hysterectomies found that adjuvant chemotherapy as treatment for their early-stage, intermediate-risk cervical carcinoma did not improve outcomes … Read more
TOPLINE: In patients with locally advanced rectal cancer who receive neoadjuvant therapy, radiation dose intensification improves pathologic complete response but leads to a small increase in acute toxicities. METHODOLOGY: Preoperative radiochemotherapy is standard of care for treating locally advanced rectal cancer, but 20%-30% of the patients develop metastatic disease. Although radiation dose escalation has been … Read more